Cytokine abnormalities in schizophrenia: a review of their pathogenic significance, with particular reference to the autoimmune hypothesis

  • R. Ganguli
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Over the past 65 years, a variety of immunologic abnormalities have been reported in association with schizophrenia. These abnormalities have included alterations in lymphocyte subpopulations, alterations in immunoglobulin production both quantitatively and qualitatively, and altered cytokine physiology (for a review see Ganguli etal., 1994). Of these immunologic findings reported in association with schizophrenia, changes in cytokine physiology appear to be the most consistent and uncontroversial. This chapter will focus primarily on the evidence of cytokine abnormalities in a subgroup of patients, and will place these findings in the framework of the hypothesis that, for this subgroup of patients, an autoimmune process may play a pathogenetic role in their disorder. First, however, since this area of research remains mired in controversy and skepticism (DeLisi, 1996), some methodologic issues will be addressed, which pertain to the theoretical and practical aspects of study design and interpretation of results.


Schizophrenic Patient Newcastle Disease Virus Immunologic Abnormality Bioi Psychiatry Cytokine Abnormality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Araujo DM, Lapchak PA, Collier B, Quirrion R (1989) Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system. Brain Res 498:257–266PubMedCrossRefGoogle Scholar
  2. Barak V, Barak Y, Levine J, Nisman B, Roisman (1995) Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6: 61 – 69PubMedCrossRefGoogle Scholar
  3. Becker D, Kritschmann E, Floru S, Shlomo-David Y, Gotlieb-Stematsky T (1990) Serum interferon in first psychotic attack. Br J Psychiatry 157: 136 – 138PubMedCrossRefGoogle Scholar
  4. Benvemoste EN (1992) Inflammatory cytokines within the central nervous system: cources, function, and mechanism of action. Am J Physiol 263 (Cell Physiol 32): C1 – C16Google Scholar
  5. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A (1995) Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38: 297 – 302PubMedCrossRefGoogle Scholar
  6. DeLisi LE (1996) Is there a viral or immune dysfunction etiology to schizophrenia? Re-evaluation a decade later. Schizophr Res 22: 1 – 4PubMedCrossRefGoogle Scholar
  7. Denicoff KD, Rubinoff DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA (1987) The neuropsychiatry effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107: 293 – 300PubMedGoogle Scholar
  8. Ellison MD, Krieg RJ, Povlishock JT (1990) Differential central nervous responses following single and multiple recombinant interleukin-2 infusions. J Neuroim-munol 28: 259 – 260Google Scholar
  9. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontant A (1989) On the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases. Eur J Immunol 19: 689 – 694PubMedCrossRefGoogle Scholar
  10. Ganguli R, Rabin BS (1989) Differences in interleukin-2 production in blacks and whites. N Engl J Med 320: 399PubMedGoogle Scholar
  11. Ganguli R, Rabin BS, Belle SH (1989) Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 26: 427 – 430PubMedCrossRefGoogle Scholar
  12. Ganguli R, Brar JS, Solomon W, Chengappa KNR, Rabin BS (1992) Altered inter¬leukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 44: 113 – 123PubMedCrossRefGoogle Scholar
  13. Ganguli R, Brar JS, Chengappa KNR, Yang ZW, Nimgaonkar VL, Rabin BS (1993) Autoimmunity in schizophrenia: a review of recent findings. Ann Med 25: 489 – 496PubMedCrossRefGoogle Scholar
  14. Ganguli R, Yang ZW, Schurin G, Chengappa KNR, Brar JS, Gubbi AV etal. (1994) Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51: 1 – 10.PubMedCrossRefGoogle Scholar
  15. Gattaz WF, Dalgalarrondo P, Schroder HC (1992) Abnormalities in serum concentra¬tions of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected. Schizophr Res 6: 237 – 241PubMedCrossRefGoogle Scholar
  16. Gutierrez EG, Banks WA, Kastin AJ (1993) Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol 45: 137 – 146CrossRefGoogle Scholar
  17. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H (1991) Inter-leukin-6 improves the survival of mesencephalic catochelaminergic and septal cholinergic neurons from patnatal, two-week-old rats in cultures. Neuroscience 40: 445 – 452PubMedCrossRefGoogle Scholar
  18. Hanisch UK, Seto D, Quirion R (1993) Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J Neurosci 13: 3368 – 3374PubMedGoogle Scholar
  19. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H (1995) Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 15: 237 – 242PubMedCrossRefGoogle Scholar
  20. Inglot AD, Leszek J, Piasecki E, Sypula A (1994) Interferon responses in schizophre¬nia and major depressive disorders. Biol Psychiatry 35: 464 – 473PubMedCrossRefGoogle Scholar
  21. Katila H, Cantell K, Hirvonen S, Rimon R (1989) Production of interferon-α and -γ by leukocytes from patients with schizophrenia. Schizophr Res 2: 361 – 365PubMedCrossRefGoogle Scholar
  22. Kaye WA, Adri MN, Soeldner JS, Rabinowe SL, Kaldany A, Kahn CR etal. (1986) Acquired deficit in interleukin-2 production in patients with type I diabetes mellitus. N Engl J Med 315: 920 – 924PubMedCrossRefGoogle Scholar
  23. Kirch DG, Kaufmann CA, Papadopoulos NM, Martin B, Weinberger DR (1985) Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol Psychiatry 20: 1039 – 1046PubMedCrossRefGoogle Scholar
  24. Kroemer G, Andreu JL, Gonzalo JA, Martinez C (1991) Interleukin-2, autotolerance, and autoimmunity. Adv Immunol 50: 147 – 235PubMedCrossRefGoogle Scholar
  25. Lapchak PA (1992) A role for interleukin-2 in the regulation of striatal dopaminergic function. Neuroreport 3: 165 – 168PubMedCrossRefGoogle Scholar
  26. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 150: 1408 – 1410PubMedGoogle Scholar
  27. Maes M, Meltzer HY, Bosnians E (1994) Immune-inflammatory markers in schizo-phrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89: 346 – 351PubMedCrossRefGoogle Scholar
  28. Maes M, Bosnians E, Meltzer HY (1995) Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and Cortisol. Eur Arch Psychiatry Clin Neurosci 245: 172 – 178PubMedCrossRefGoogle Scholar
  29. McAllister CG, vanKammen DP, Rehn TJ, Miller AN, Gurklis J, Kelley ME, Yao J, Peters JL (1995) Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrance of psychosis and medication status. Am J Psychiatry 152: 1291 – 1297PubMedGoogle Scholar
  30. McKusick VA (1969) On lumpers and splitters, or the nosology of genetic disease. Nosology of Genetic Disease Perspectives in Biology and Medicine (Winter): 298 – 312Google Scholar
  31. Muller N, Ackenheil M (1995) Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: the relationship to negative symptomatology. Schizophr Res 14: 223 – 228PubMedCrossRefGoogle Scholar
  32. Muller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R (1991) Cellular immunity in schizophrenic patients before and during neuroleptic therapy. Psychiatry Res 37: 147 – 160PubMedCrossRefGoogle Scholar
  33. Nance DM, Rayson D, Carr RI (1987) The effects of lesions in the lateral septal and hippocampal areas on the humoral immune response of adult female rats. Brain Behav Immun 1: 292 – 305PubMedCrossRefGoogle Scholar
  34. Nemni R, Iannaccone S, Quattrini A, Smirne S, Sessa M, Lodi M, Ermino C, Canal N (1992) Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice. Brain Res 591: 248 – 252PubMedCrossRefGoogle Scholar
  35. Nistico G, De Sarro G (1991) Is interleukin-2 a neuromodulator in the brain? TINS 14: 146 – 150PubMedGoogle Scholar
  36. Norris JG, Benveniste EN (1993) Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol 45: 137 – 146PubMedCrossRefGoogle Scholar
  37. Plata-Salaman CR (1991) Immunoregulators in the nervous system. Neurosci Behav Rev 15: 185 – 215CrossRefGoogle Scholar
  38. Reiner SL, Locksley RM (1995) The regulation of immunity to leishmania major. Annu Rev Immunol 13: 151 – 177PubMedCrossRefGoogle Scholar
  39. Roitt IM, Doniach D, Campbell PN, Hudson RV (1956) Autoantibodies in Hashimoto’s disease. Lancet ii: 820 – 821Google Scholar
  40. Rose NR, Witebsky E (1956) Studies on organ specificity. V. Changes in the thyroid glands of rabbit following active immunization with rabbit thyroid extracts. J Immunol 76: 417 – 427PubMedGoogle Scholar
  41. Saris SC, Rosenberg SA, Friedman RB, Rubin JT, Barba D, Oldfield EH (1988) Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 69: 29 – 34PubMedCrossRefGoogle Scholar
  42. Sawada M, Suzumura A, Marunouchi T (1992) TNF-alpha induces IL-6 production by astrocytes, but not by microglia. Brain Res 583: 296 – 299PubMedCrossRefGoogle Scholar
  43. Sharief MK, Hentges R, Ciardi M, Thompson EJ (1993) In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis. J Neurol 240: 46 – 50PubMedCrossRefGoogle Scholar
  44. Shintani F, Kanba S, Maruo N, Nakaki T, Nibuya M, Suzuki E et al. (1991) Serum interleukin-6 in schizophrenic patients. Life Sci 49: 661 – 664PubMedCrossRefGoogle Scholar
  45. Shintani F, Kanba S, Nakaki T, Nibuya M, Kinoshita N, Suzuki E, Yagi G, Kato R, Asai M (1993) Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 13: 3574 – 3581PubMedGoogle Scholar
  46. Smith RS (1991) Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocytes? Med Hypotheses 34: 225 – 229PubMedCrossRefGoogle Scholar
  47. Smith RS (1992) A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 39: 248 – 257PubMedCrossRefGoogle Scholar
  48. Tsuang MT, Faraone SV (1995) The case for heterogeneity in the etiology of schizophrenia. Schizophr Res 17: 161 – 175PubMedCrossRefGoogle Scholar
  49. Villemain F, Chatenoud L, Galinowski A, Homo DF, Ginestet D, Loo H et al. (1989) Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 146: 609 – 616PubMedGoogle Scholar
  50. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Homberg M, Kirchner H (1996) Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246: 273 – 278CrossRefGoogle Scholar
  51. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Green- berg AH (1994) Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643:40–49PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • R. Ganguli
    • 1
  1. 1.Western Psychiatric Institute & ClinicUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations